Familial Adenomatous Polyposis Clinical Trial
Official title:
Molecular Targeting of 15-LOX-1 for Apoptosis Induction in Human Colorectal Cancers
Primary Objective: - To determine whether celecoxib downregulates GATA-6 expression to upregulate 15-LOX-1 expression and induce apoptosis in human rectal tumors, researchers will measure GATA-6 and 15-LOX-1 expression, 13-S-HODE levels, and apoptosis rates in normal and colorectal polyp epithelial tissues before and after 6 months of celecoxib treatment of patients with familial adenomatous polyposis (FAP).
Celecoxib is a drug that was developed to treat arthritis. However, celecoxib may also help to stop or slow the growth of colon and rectal tumor cells. At the start of the study, you will be asked questions about your medical history, have a complete physical exam, and have around 2 tablespoons of blood drawn for blood tests as part of your routine care for familial adenomatous polyposis. Also, blood tests such as fasting blood glucose and lipid profiling (cholesterol, LDL, HDL and triglyceride) will be assessed to determine eligibility. Women who are able to have children must have a negative blood pregnancy test within 14 days of starting celecoxib. Before your scheduled colonoscopy, you will fill out a form asking about any medications and nutritional supplements that you are taking. In addition, you will be asked to complete a diet history. This will help researchers to evaluate patients' dietary habits. The questionnaire takes about 15 minutes to complete. You will also have around 1 teaspoon of blood drawn to measure the amount of celecoxib in your blood. Then, during your already scheduled colonoscopy procedure, you will have additional tissue biopsies (the size of a pencil tip) of your colon taken. For a colonoscopy procedure, a flexible tube with a light attached to the end is used to look inside your colon/lower gut. The biopsies will be taken through the flexible tube using a special cutting tool. Up to 23 biopsy samples may be taken. The biopsies should take about 20 extra minutes to complete. After the procedure, you will start taking celecoxib by mouth once every 12 hours for 6 months. You will also have around 1 teaspoon of blood drawn to measure the amount of celecoxib in your blood at the completion of month 2 and 4 of celecoxib treatment. At the end of the 6 month treatment period, you will have another colonoscopy procedure. This is an additional procedure performed solely for this study and is not part of your standard of care for the treatment of familial adenomatous polyposis. A second set of biopsies will be taken (23 maximum). These biopsy samples will be studied and compared to the samples taken before treatment with celecoxib. You will also have around 1 teaspoon of blood drawn to measure the amount of celecoxib in your blood. You will be contacted by phone 72 hours after your first dose of celecoxib and then every 2 weeks for the study to check for any side effects you may be experiencing. The maximum amount of time you will remain on this study is 6 months. If at any time, you experience any intolerable side effects, you will be taken off the study. This is an investigational study. Celecoxib is FDA approved and commercially available for familial adenomatous polyposis patients to reduce polyp formation. Up to 40 patients will take part in this study. All will be enrolled at M. D. Anderson. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05630794 -
Testing ONC201 to Prevent Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02961374 -
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
|
Phase 2 | |
Completed |
NCT01483144 -
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
|
Phase 3 | |
Completed |
NCT00641147 -
Curcumin in Treating Patients With Familial Adenomatous Polyposis
|
Phase 2 | |
Recruiting |
NCT03471403 -
Cold Snare Polypectomy for Duodenal Adenomas in Familial Adenomatous Polyposis
|
||
Not yet recruiting |
NCT04531930 -
Colorectal Adenoma Canceration in FAP
|
||
Recruiting |
NCT04677998 -
A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis
|
||
Recruiting |
NCT04678011 -
A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy
|
||
Completed |
NCT00927485 -
Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
|
N/A | |
Recruiting |
NCT00253812 -
Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy
|
N/A | |
Withdrawn |
NCT00248053 -
Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients
|
Phase 2 | |
Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|
||
Completed |
NCT04674228 -
Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01
|
||
Completed |
NCT01656746 -
Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease
|
N/A | |
Completed |
NCT00808743 -
Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03847636 -
CryoBalloon Ablation for Treatment of Duodenal Adenomas
|
N/A | |
Not yet recruiting |
NCT05112822 -
Testing Obeticholic Acid (OCA) for Familial Adenomatous Polyposis (FAP)
|
Phase 1 | |
Recruiting |
NCT02656134 -
Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP)
|
N/A | |
Withdrawn |
NCT01245816 -
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
|
Phase 3 | |
Recruiting |
NCT04709445 -
Perfusion Rate Assessment by Near-infrared Fluorescence in Gastrointestinal Anastomoses
|
N/A |